Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) EBITDA (2016 - 2025)

Lisata Therapeutics (LSTA) has disclosed EBITDA for 12 consecutive years, with -$4.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA rose 17.28% year-over-year to -$4.4 million, compared with a TTM value of -$20.1 million through Sep 2025, up 14.5%, and an annual FY2024 reading of -$22.4 million, up 12.83% over the prior year.
  • EBITDA was -$4.4 million for Q3 2025 at Lisata Therapeutics, up from -$4.9 million in the prior quarter.
  • Across five years, EBITDA topped out at -$4.4 million in Q3 2025 and bottomed at -$6.9 million in Q2 2023.
  • Average EBITDA over 3 years is -$5.7 million, with a median of -$5.5 million recorded in 2024.
  • Peak annual rise in EBITDA hit 19.67% in 2024, while the deepest fall reached 1.43% in 2024.
  • Year by year, EBITDA stood at -$6.0 million in 2023, then rose by 17.86% to -$4.9 million in 2024, then rose by 10.81% to -$4.4 million in 2025.
  • Business Quant data shows EBITDA for LSTA at -$4.4 million in Q3 2025, -$4.9 million in Q2 2025, and -$5.8 million in Q1 2025.